Wed, Sep 17, 2014, 3:53 PM EDT - U.S. Markets close in 7 mins.


% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • jsblvbjb jsblvbjb Oct 16, 2013 10:03 AM Flag

    Hey kvn, you sold "everything" too soon...

    Market's way up today. Glad you held your INSM, though! I think you've failed to realize that WS will shut its purse to Washington if the Political Chil'ens can't get a compromise worked out. I hope you don't pay too close attention to what the Man in the House is saying, it's deceptive and deceitful at best. I prefer to use my own rationale and mental ability without any political nudging! More news on the way this week!!!!

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Try to get a hold of yesterdays after hours upgrade by ****** and you might start adding shares with the new price target they have indicated and make sure KVN reads it.I am glad he didn't sell his Insmed shares as well.Sorry that i can't post it on line.
      Like i posted yesterday Lewis is new our Santa Claus.
      Do your own research please.
      Best regards

      Sentiment: Strong Buy

      • 3 Replies to levonchiko
      • Levonchiko......Who is supposed to have upgraded after hours yesterday? I don't see anything.....where am I going wrong?? (LOL). Anyway, wouldn't we be hearing something from flyonthewall about this? We normally do.


      • levonchiko, Albeto sent me the link and I agree and added more. Thank you guys for keeping an old man like me in the loop.


      • This is all I could find. Does anyone have anything to add?
        Analyst Joseph Schwartz tells salesforce encouraged by INSM announcement that enrollment of TARGET-NTM (nontuberculous mycobacterial) is complete, co.'s initial powering assumptions have been validated. Notes INSM has powered trial at 80% to demonstrate a one-step change on sevenstep bacterial density scale, but his conversations with MEDACorp KOLs (key opinion leaders), analysis of limited clinical aerozolized Amikacin data generated in refractory NTM patients and animal models suggest Arikace's treatment effect could be much greater. Has $22 price target. M.Morrow

        Sentiment: Strong Buy

    • Most will believe the "default" lie that the media is pushing. The Treasury brings in 200B a month and debt servicing is about 20B. Further the 14th Amendment says this has to be paid. If the President tries to tank the economy by not paying it, that would be an impeachable Offense. Repeat a lie enough times.....
      Other than that....Go INSM!!!

      Sentiment: Strong Buy

13.30+0.05(+0.38%)3:52 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.